

CMBI Credit Commentary**Fixed Income Daily Market Update 固定收益部市场日报****The Asset Asian G3 Bond Benchmark Review 2023**

We hope you found our commentaries and ideas helpful. We seek to elevate our efforts and value-add further in the coming year. We highly appreciate your support to us in Sell-Side Analysts of the polls of "[The Asset Asian G3 Bond Benchmark Review 2024](#)". Thank you for your support!

- *Market sentiment remained weak this morning. New issue GRWALL Perp rallied 0.5pt higher while GRWALL'28 was unchanged. Asian IG space was stable with better selling flows.*
- ***BBLTB**: FV of new 10y USD bonds to be T+125-135. BBLTBs widened 1-3bps this morning. We have buy recommendation on **BBLTB 5 Perp** and **KBANK 5.275 Perp** among Asian EM banks. See below.*
- ***MEDCIJ**: Upgraded to BB- by S&P. Maintain buy on MEDCIJs. MEDCIJs were unchanged to 0.1pt higher. See below*

❖ Trading desk comments 交易台市场观点

Yesterday, the new LGENSO 27/29/34 closed 7-10bps wider from the ROs. HYUELE 29-33s were 3-5bps wider. KRKPSC 27s/29s were 2-6bps wider. SIASP 29s widened 1bp, while OCBCSP 30s/34s were 1-2bps tighter. Chinese IGs remained soft. HAOHUA '30/SINOCHE '31 were 1bp wider. TENCNT/BIDU 30s were 3bps wider. MEITUA '30 widened 8bps. Media reported on Meituan's plan to issue USD1bn bonds for debt repayments and expansion. In financials, BOCAVI 24-33s widened 4-6bps on heavy selling. In Chinese AMCs, GRWALL priced a USD200mn 3.5-yr bond at T+195, and a USD300mmn NC3 Perp at par to yield 7.15%. We consider they are fairly priced. GRWALL 3.95 Perp was unchanged to 0.1pt higher. The new GRWALL 7.15 Perp opened 0.5pt higher from par. ORIEAS/CCAMCL 29s were 2-3bps wider. In AT1s, INTNED 3.875 Perp/BACR 4.375 Perp/BNP 6.875 Perp were 0.1-0.3pt higher despite some profit taking. Meanwhile Canadian names RY 7.408 Perp/BNS 4.9 Perp/BMO 4.8 Perp were sought-after and closed unchanged to 0.1pt higher. In HK, BNKEA/AIA/CKHH/DAHSIN/PINGIN 33-34s widened 4-8bps. NWDEVL Perps were 1.4-2.7pts higher and NWDEVL 27-31s were up 1.1-1.4pts, following further progress on its refinancing. See our comments on 25 Jun'24. LIHHK '26 was 1.2pts higher, while AIA 44/46 were down 1.1-1.8pts. Chinese properties were mixed. ROADKG Perps/24-26s were 0.6-1.0pt higher. VNKRLE 25-29s declined another 1.9-3.0pts and closed 3.7-4.9pts lower. WTD. FTLNHD/FUTLAN 24-26s were 0.3-0.9pt lower. Outside properties, HILOHO '24/FOSUNI '27 were 0.6pt lower. In Macau gaming, MPEL 28-29s were 0.6-1.0pt lower. In Indonesia, LMRTSP/LPKRIJ 26s were 0.4pt higher.

Glenn Ko, CFA 高志和
(852) 3657 6235
glennko@cmbi.com.hk

Cyrena Ng, CPA 吳倩瑩
(852) 3900 0801
cyrenang@cmbi.com.hk

Jerry Wang 王世超
(852) 3761 8919
jerrywang@cmbi.com.hk

There were better selling flows in the higher-yielding LGFVs and high-beta IG names, and we saw investors raised cash for new issues and attempted to lock in profits for the in-the-money positions. GSHIAV '25 was 0.2pt lower. SDGOLD '26 was down 0.3pt. CPDEV 25/26/Perp and ZHHFGR '26 were 0.1pt lower. In the high beta names, CWAHK '26 was 0.7pt higher. GRPCIN/SUNSHG 26s were up 0.1-0.2pt.

❖ Last Trading Day's Top Movers

Top Performers	Price	Change	Top Underperformers	Price	Change
NWDEVL 5 1/4 PERP	80.8	2.7	VNKRLE 3 1/2 11/12/29	52.1	-3.0
NWDEVL 4 1/8 PERP	60.1	2.6	VNKRLE 3.975 11/09/27	60.0	-2.5
NWDEVL 6.15 PERP	96.9	2.5	VNKRLE 3.15 05/12/25	82.8	-1.9
NWDEVL 6 1/4 PERP	53.8	2.0	AIA 4 7/8 03/11/44	94.0	-1.8
NWDEVL 4 1/2 05/19/30	75.2	1.5	AIA 4 1/2 03/16/46	89.3	-1.1

❖ Marco News Recap 宏观新闻回顾

Macro – S&P (+0.39%), Dow (-0.76%) and Nasdaq (+1.26%) were mixed on Tuesday. US Conference Board Jun'24 consumer confidence was 100.4, higher than the expectation of 100. UST yield retreated yesterday, 2/5/10/30 yield reached 4.65%/4.25%/4.23%/4.36%.

❖ Desk analyst comments 分析员市场观点

➤ BBLTB: FV of new 10y USD bonds to be T+125-135

We consider the FV of Bangkok Bank (M/S/F issuer rating: Baa1/BBB+/BBB) proposed 10y senior unsecured bonds (M/S/F issue rating: Baa1/BBB+/-) to be T+125-135 (YTM of 5.51%-5.61%) compared with the IPG of T+165, in view of the existing senior BBLTB 5.5 09/21/33 (M/S/F issue rating: Baa1/BBB+/-) of T+120 (Ask YTM of 5.48%) with tenor premium.

BBLTB 5 ½ 09/21/33	
YTM	5.48
T-Spread	120
Maturity	21 Sep'33
Rating (M/S/F)	Baa1/BBB+/-
Source: Bloomberg.	

Bangkok Bank has an ample capital buffer against the regulatory requirements. As of 31 Mar'24, its CET1 ratio was 15.6% (vs. regulatory requirement of 8.0%) and the total capital ratio (CAR) was 19.7% (vs. regulatory requirement of 12.0%). Bangkok Bank has a better asset quality than major peers such as KasikornBank and Krunghai Bank with improving NIM although its capital ratios are slightly lower. See below table for key ratios of the three banks.

As of Mar'24	Bangkok Bank	KasikornBank	Krunghai Bank
CET1 ratio	15.60%	16.70%	17.50%
CAR	19.70%	18.80%	20.20%
NIM	3.06%	3.76%	3.31%
NPL ratio	3.00%	3.19%	3.14%
Coverage ratio	291.7%	150.3%	181.8%

Source: Company fillings.

We have buy recommendation on **BBLTB 5 Perp** and **KBANK 5.275 Perp** among Asian EM banks for their remote probability to be non-viable and thus the low chance of loss absorption for the AT1. BBLTB 5 Perp (callable Sep'25) is trading at YTC of 6.9% at 97.8. At 97.7, KBANK 5.275 Perp (callable Oct'25) is trading at a YTC of 7.1%.

➤ **MEDCIJ: Upgraded to BB- by S&P. Maintain buy on MEDCIJs**

S&P upgraded Medco Energi to BB- from B+ with a stable outlook. The rating upgrade reflects Medco Energi's 20.92% equity stake in Amman Mineral Internasional provides it with high degree of financial flexibility, even Medco Energi does not have any immediate plan to divest its stake in Amman. Medco's 20.92% equity stake in Amman Mineral Internasional carries a market valuation of cUSD10bn, based on its latest share price quoted on the Indonesia Stock Exchange.

Medco Energi has been proactively managing its USD bond maturities in the past two years. It fully redeemed MEDCIJ 6.75 01/30/25 with an outstanding amount of USD33mn at redemption price of 100.84 on 6 May'24. It also repurchased USD148.8mn of MEDCIJ'26 in the tender offers completed on 6 Jun'24. Recalled that it repurchased USD397mn of four USD bonds in Nov'23 with concurrent new issuance of USD500mn MEDCIJ'29, and repurchased USD265mn of MEDCIJ'25 in Nov'22 via tender offers.

Fitch upgraded Medco Energy to BB- with stable outlook on 29 Apr'24 on its improvement in reserve life. We maintain buy on MEDCIJs. Within MEDCIJ curve, we prefer MEDCIJ 6.95 11/12/28 for lower cash price and more balanced risk-return profile.

Security Name	ISIN	Amt Out (USD mn)	Ask Price	YTM (Ask,%)	Rating (M/S/F)
MEDCIJ 7 ¾ 05/14/26	US58405FAA30	314.73	101.20	6.68	B1/BB-/BB-
MEDCIJ 6 ¾ 01/30/27	US58406LAA98	498.68	98.22	7.14	B1/BB-/BB-
MEDCIJ 6.95 11/12/28	US58406RAA68	299.42	97.57	7.61	B1/BB-/BB-
MEDCIJ 8.96 04/27/29	US58407HAA77	500	104.83	7.74	B1/BB-/BB-

Source: Bloomberg.

➤ **Offshore Asia New Issues (Priced)**

Issuer/Guarantor	Size (USD mn)	Tenor	Coupon	Priced	Issue Rating (M/S/F)
China Great Wall	200	3.5yr	6.375%	T+195	-/-/BBB-
China Great Wall	300	PNC3	7.15%	7.15%	-/-/BB+
Indonesia	750/1000/600	5/10/30yr	5.1%/5.2%/5.5%	5.1%/5.2%/5.5%	Baa2/BBB/BBB
NTT Finance	600/900/850	3/5/7yr	5.104%/5.11%5.16%	T+65/85/90	A1/A/-
Sumitomo Corporation	500/500	5/10yr	5.05%/5.35%	T+80/110	Baa1/A/-

➤ **Offshore Asia New Issues (Pipeline)**

Issuer/Guarantor	Currency	Size (USD mn)	Tenor	Pricing	Issue Rating (M/S/F)
Bangkok Bank HK Branch	USD	-	10yr	T+165	Baa1/BBB+/-
China Huaneng Group	USD	-	PNC3	5.85%	A3/-/-
Cathay Life Insurance	USD	-	10yr	T+205	-/BBB+/BBB+
Huzhou Nanxun Tourism	USD	-	3yr	7.0%	-/-/-
Macquarie Bank	USD	-	3yr	T+95/SOFR Equiv	Aa2/A+/A+
Mitsubishi Corp	USD	-	5yr	T+100	A2/A/-

NongHyup Bank	USD	-	3/5yr	-	-/-
Samvardhana Motherson	USD	-	5yr	-	Baa3/-/BBB-
Swire Pacific	USD	-	5yr	T+120	A3/-

➤ News and market color

- Regarding onshore primary issuances, there were 137 credit bonds issued yesterday with an amount of RMB103bn. As for month-to-date, 1,605 credit bonds were issued with a total amount of RMB1,556bn raised, representing a 13.4% yoy increase
- [ADEIN]** Media reported that Adani Group plans USD15.6bn capex and raise USD2-2.5bn equity capital in FY25 ending 31 Mar'25
- [ADSEZ]** S&P affirmed Adani Ports BBB- rating and changed rating outlook to positive
- [CPDEV]** S&P affirmed Beijing Capital Group BBB- ratings with stable outlook
- [LNGFOR]** Media reported that Longfor repaid HKD1.6bn of originally HKD8.75bn due-Jan'25 loan and aims to repay the remaining amount in 2024. Longfor raised RMB20bn of new loans secured by its commercial properties in 5M24
- [MEITUA]** Media reported that Meituan is considering bond offering more than USD1bn to repay debts and finance expansion plans
- [SHIMAO]** Media reported that Shimao Group is seeking to secure support from creditors for offshore debt restructuring by sweetening offer
- [SKONKR]** Media reported that SK On plans to issue cUSD360mn 6.424% perpetual domestic perp to boost liquidity

Fixed Income Department

Tel: 852 3657 6235/ 852 3900 0801

fis@cmbi.com.hk

CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)

Author Certification

The author who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the author covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that author in this report.

Besides, the author confirms that neither the author nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM and/or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

Disclaimer:

For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.